3rd Quarter - Report

AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. for AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC

Firm
Client
Income
—
Expenses
$1,230,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Transportation TRA

Issues relating to requirements for ride hailing vehicles and companies, S. 1871, Samis Law. Issues relating to highway/transportation reauthorization and appropriations.

LobbyistCovered position, as disclosed
OKEYSHA BROOKS-COLEY —
GREGG HAIFLEY —

Contacted: Health & Human Services, Dept of (HHS); State, Dept of (DOS); Federal Trade Commission (FTC); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); U.S. Agency for International Development (USAID); White House Office; HOUSE OF REPRESENTATIVES; Energy, Dept of; Environmental Protection Agency (EPA); Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Labor, Dept of (DOL); Veterans Affairs, Dept of (VA); SENATE

Bills named: S. 1871 (116th)

Taxation/Internal Revenue Code TAX

Issues regarding expanding the availability of the charitable deduction for non-itemizers, issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues respecting the medical expense deduction. Issues related to charitable IRA rollovers, including H.R. 3832 and S. 1257, the Legacy IRA Act.

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
GREGG HAIFLEY —
CAROLINE POWERS —
DENYS C SYMONETTE —

Contacted: Labor, Dept of (DOL); Federal Trade Commission (FTC); Natl Institutes of Health (NIH); Environmental Protection Agency (EPA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Energy, Dept of; White House Office; State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); SENATE; Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); U.S. Agency for International Development (USAID); Veterans Affairs, Dept of (VA)

Bills named: S. 1257 (116th), H.R. 3832 (116th)

Health Issues HCR

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law. Issues relating to FDA regulation of laboratory tests, Verifying Accurate Leading-edge IVCT Development Act of 2018 or the VALID Act of 2018; H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing disparities in cancer clinical trials; Issues related to improving quality of life for cancer survivorship; H.R. 1948 & S. 518, the Lymphedema Treatment Act H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; and Cannabis research issues, including S. 2032. H.R. 2689 & S. 1438 the Breast Cancer Research Stamp Reauthorization Act H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 HR___, Medical Records Fairness Act (Rep. Bill Foster, D-IL) S. 2497, the Dependent Income Exclusion Act SJ Res 52, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Secretary of the Treasury and the Secretary of Health and Human Services relating to "State Relief and Empowerment Waivers". Issues related to prescription drug costs - H.R. 3, the Lower Prescription Drug Costs Now Act and S. 2543, the Prescription Drug Pricing Reduction Act of 2019 H.R. 4439, Creating Hope Reauthorization Act

Contacted: Labor, Dept of (DOL); Food & Drug Administration (FDA); Environmental Protection Agency (EPA); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Natl Institutes of Health (NIH); SENATE; Energy, Dept of; Veterans Affairs, Dept of (VA); Health & Human Services, Dept of (HHS); White House Office; U.S. Agency for International Development (USAID); Federal Trade Commission (FTC); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 647 (116th), H.Res. 14 (116th), S. 518 (116th), H.R. 1730 (116th), H.R. 4897 (116th), H.R. 2222 (116th), H.R. 4439 (116th), S. 2032 (116th), S. 1438 (116th), S. 2358 (116th), H.Res. 282 (116th), S. 1107 (116th), H.R. 2689 (116th), S. 1719 (116th), H.R. 3630 (116th), H.R. 1966 (116th), S. 2080 (116th), H.R. 1409 (116th), H.R. 1948 (116th), S.Res. 223 (116th), H.R. 4078 (116th), S. 2497 (116th), H.R. 3 (116th), S. 2543 (116th), H.R. 1028 (116th), S. 741 (116th), S.J.Res. 52 (116th), S. 2424 (116th)

Medicare/Medicaid MMM

Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including: HR 1570 and S. 668, the Removing Barriers to Colorectal Cancer Screening Act, and regulatory issues related to the Medicare coinsurance issue in these bills; HR 3835, the Cancer Care Planning and Communications Act; CMS-issued regulations pertaining to Medicare Part B reimbursement - the CY2020 Medicare Physician Fee Schedule; HR 913, The CLINICAL TREATMENT Act, Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trial; Issues related to potential Administration guidance relating to giving states the option to block grant their Medicaid program; Issues related to Puerto Ricos Medicaid program, including H.R. 3631, Territories Health Care Improvement Act; H.R. 3, the Lower Drug Prices Now Act - legislation for lowering prescription drug costs, lowering out of pocket expenses for Medicare beneficiaries, and placing a cap on Medicare Part D; S. 2543, the Prescription Drug Pricing Reduction Act of 2019 - legislation for lowering prescription drug costs, lowering out of pocket costs for Medicare beneficiaries, and placing a cap on Medicare Part D; and Issues related to Medicaid Non-Emergency Medical Transportation.

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); White House Office; Labor, Dept of (DOL); Federal Trade Commission (FTC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); State, Dept of (DOS); Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); Energy, Dept of; U.S. Agency for International Development (USAID); Environmental Protection Agency (EPA)

Bills named: H.R. 1570 (116th), S. 2543 (116th), H.R. 3835 (116th), S. 668 (116th), H.R. 913 (116th), H.R. 3 (116th), H.R. 3631 (116th)

Budget/Appropriations BUD

FY 2020 federal appropriations for cancer research and prevention funding at the NIH, NCI and CDC; policy issues and funding related to the CDCs and FDAs tobacco work; issues and funding related to non-communicable diseases; funding for cancer programs within the CDMRP; funding for development of nuclear isotopes for medical diagnostic technology; issues related to global health funding for cervical cancer screening & treatment and HPV vaccination; and and issues related to highway authorization and appropriations.

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
GREGG HAIFLEY —
CAROLINE POWERS —
DENYS C SYMONETTE —

Contacted: Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Energy, Dept of; HOUSE OF REPRESENTATIVES; Environmental Protection Agency (EPA); Food & Drug Administration (FDA); Veterans Affairs, Dept of (VA); Federal Trade Commission (FTC); State, Dept of (DOS); Health & Human Services, Dept of (HHS); Labor, Dept of (DOL); U.S. Agency for International Development (USAID); White House Office; SENATE; Centers For Disease Control & Prevention (CDC)

Tobacco TOB

Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments, including: Implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the FDA deeming regulation; Issues relating to FDA regulation of electronic cigarettes and cigars; S. 655 and H.R.1498, Stopping Appealing Flavors in E-Cigarettes for Kids Act; S. 1048 and H.R. 2111, Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction Act; H.R.1854 & S.9, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 2084, the Stopping Consumption of Tobacco by Teens Act of 2019; H.R. 2339, Reversing the Youth Tobacco Epidemic Act of 2019; S. 1258 and H.R. 2411, Tobacco to 21 Act; Issues related to FDA tobacco control to be considered in House and Senate in the FY20 Agriculture Appropriations legislation and CDC tobacco activities as considered in the Labor, Health and Human Services Appropriations legislation; H.R. 293, Youth Vaping Prevention Act of 2019; S. 616, E-Cigarette youth Protection Act; S. 1253, Preventing Online Sales of E-Cigarettes to Children Act; S. 1541, Tobacco-Free Youth Act; S. 1895, Lower Health Care Costs Act regarding tobacco 21 age of sale provisions; S 1832, Smoke-Free Schools Act; S. 2726, Banning Smoking on Amtrak Act of 2019; and Issues related to smoke-free policies for the Veterans Health Administration, H.R. 3700 and S. 2106. Issues related to electronic cigarettes: H.R. 4249, Stop Vaping Ads Act; S. 2550, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; H.R. 4425, Quell Underage Inhaling of Toxic Substances Act of 2019; and S. 2519, Ending New Nicotine Dependencies Act of 2019 (ENND Act). Issues related to taxation of tobacco products: and S. 2463, E-cigarette Tax Parity Act; S. 2517, Tobacco Tax Equity Act of 2019.

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
GREGG HAIFLEY —
CAROLINE POWERS —
DENYS C SYMONETTE —

Contacted: U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Energy, Dept of; SENATE; Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Federal Trade Commission (FTC); Environmental Protection Agency (EPA); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); Labor, Dept of (DOL); State, Dept of (DOS); Centers For Disease Control & Prevention (CDC); White House Office

Bills named: H.R. 2084 (116th), H.R. 2411 (116th), S. 1048 (116th), S. 2726 (116th), S. 2106 (116th), H.R. 1498 (116th), S. 1541 (116th), S. 1253 (116th), H.R. 2111 (116th), H.R. 3700 (116th), S. 2519 (116th), H.R. 1854 (116th), S. 9 (116th), H.R. 2339 (116th), H.R. 293 (116th), S. 1895 (116th), S. 1258 (116th), S. 2463 (116th), H.R. 4425 (116th), S. 2550 (116th), S. 655 (116th), H.R. 4249 (116th), S. 2517 (116th), S. 616 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.